Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
AngioDynamics ( (ANGO) ) has issued an update.
On January 16, 2025, AngioDynamics’ CEO, James Clemmer, presented at the J.P. Morgan 43rd Annual Healthcare Conference, highlighting the company’s strategic direction and future financial outlook. The presentation underscored AngioDynamics’ commitment to innovation and growth, with expectations to achieve adjusted EBITDA positivity by FY2025 and cash flow positivity by FY2026. The company is poised for sustained growth, focusing on expanding its Med Tech segment and optimizing its portfolio through strategic initiatives, despite the challenges posed by economic conditions and regulatory landscapes.
More about AngioDynamics
AngioDynamics, Inc. is a diversified medical technology company that focuses on expanding treatment options and improving patient outcomes in cardiovascular disease and cancer. With a strong track record in portfolio management, research and development, clinical and regulatory expansion, the company operates through two global reporting segments: Med Tech and Med Device. AngioDynamics aims for sustainable revenue growth and profitability, leveraging innovative platform technologies and maintaining a robust balance sheet.
YTD Price Performance: 35.52%
Average Trading Volume: 635,545
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $477.5M
For a thorough assessment of ANGO stock, go to TipRanks’ Stock Analysis page.
